Sm08502-onc-01

Author: xxzi

August undefined, 2024

WebbORG STUDY ID : SM08502-ONC-01 NCT ID : NCT03355066 Conditions Solid Tumor, Adult Interventions Purpose This study is an open-label, multi-center, dose-escalation, dose … Webb13 dec. 2024 · SM08502 inhibited cell viability in all 14 cell lines (regardless of KRAS status) (EC 50 =0.072-0.526 μM). In Capan-1, HPAFII, and Panc1 cells, 1 μM SM08502 …

ClinConnect NCT03355066

Webb15 juni 2024 · DKN-01和PD-1抑制剂pembrolizumab（Keytruda）的组合最近在具有高DKK1表达的胃食管腺癌患者中显示出了希望。 ... SM08502. SM08502是CLK2 / 3的抑 … Webb16 dec. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and … scotty in a box

GI ONCOLOGY CLINICAL TRIALS AT UCDAVIS

Webb27 jan. 2024 · SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK … Webb(C) SM08502 is more potent than PRI-724 in an SW480 Wnt reporter (TOPflash) assay. Cells were treated with a 3-fold 10-point titration of doses of SM08502 or PRI-724 … WebbCANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment Salubris Biotherapeutics Announces … scotty in gumnut land

EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE …

A Study Evaluating the Safety and Pharmacokinetics of

Webb26 maj 2024 · Conclusions: In preclinical CRC models, SM08502 was a potent inhibitor of Wnt pathway signaling and gene expression. It showed strong antitumor activity in … Webb1 aug. 2024 · HEC265, SNGM, and Ishikawa-S33Y tumors all had significantly lower tumor volumes with combination of SM08502 and paclitaxel compared to single-agent … scotty ice skaterWebbCancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically … scotty in red speedos

"WebbSM08502-ONC-01: A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with … " - Sm08502-onc-01

Sm08502-onc-01

A Study Evaluating the Safety and Pharmacokinetics of Orally ...

Webb2 okt. 2024 · SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of data demonstrating a novel mechanism of action for SM08502 … http://www.usalifesciences.com/us/portal/news_details.php?news_id=28606851k$SnKVXke2weSNs

Did you know?

Webb20 okt. 2024 · Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC. Subjects will receive increasing doses of SM08502 with fixed doses of … Webb11 dec. 2024 · SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Samumed, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small …

Webb31 mars 2024 · SM08502 is a first-in-class CLK inhibitor being investigated in a Phase 1 clinical trial for subjects with advanced solid tumors (NCT03355066). Keywords: … Webb[VIRTUAL] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate …

Webb6 apr. 2024 · SM08502 (cirtuvivint) is a novel pan CDC-like kinase (CLK) and Dual specificity tyrosine kinase (DYRK) inhibitor that targets mRNA splicing and is optimized …

WebbApply to this Phase 1 clinical trial treating Non-small Cell Lung Cancer, Colorectal Carcinoma (CRC), Castration-resistant Prostate Cancer. Get access to cutting edge …

Webb17 nov. 2024 · Drug: SM08502 Study Type Interventional Enrollment (Actual) 82 Phase Phase 1 Contacts and Locations This section provides the contact details for those … scotty in pakistan priceWebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and … scotty in new star trekWebb28 nov. 2024 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors The safety and scientific validity of … scotty incWebb30 jan. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and … scotty indianaWebbCirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research [1] . Cirtuvivint (SM08502) inhibits … scotty indian packWebbLogin. Nctid: NCT03355066 Payload: scotty in 2009 star trekWebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology at Biosplice … scotty info